Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rukang Granules (乳康颗粒) is a proprietary Traditional Chinese Medicine (TCM) developed and manufactured by Xi'an Qianhe Pharmaceutical. It is an oral herbal formulation primarily indicated for the treatment of hyperplasia of mammary glands (mastopathy), breast distension, and pain. The medicine is formulated based on TCM principles to soften hardness and dissipate nodules, regulate Qi, and activate blood circulation. It is commonly prescribed for patients exhibiting symptoms of Qi stagnation and blood stasis. As a complex herbal mixture, its specific molecular mechanism of action is not defined in conventional pharmacological terms, though it is recognized for its therapeutic effects in managing benign breast diseases and was one of the products from a company noted for passing UK GMP certification.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rukang Granules.